By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lantheus Medical Imaging 

331 Treble Cove Road

North Billerica  Massachusetts  01862  U.S.A.
Phone: 800-299-3431 Fax: 978-436-7501


Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit


President and CEO: Mary Anne Heino

CFO: Jack Crowley

CMO: Cesare Orlandi, MD

VP, Manufacturing and Operations: William Dawes

General Counsel and Sr. VP Strategy and Business Development: Michael Duffy

Sr. VP, Commercial: Tim Healey

CMO: Cesare Orlandi, MD

VP, R&D: Simon Robinson

VP, Quality: Carol Walker

Key Statistics

Ownership: Public

Web Site: Lantheus Medical Imaging
Symbol: LNTH

Company News
Lantheus Medical Imaging Announces Public Offering Of 5,200,000 Shares Of Common Stock 9/9/2016 10:58:55 AM
Lantheus Medical Imaging To Host Third Quarter 2015 Earnings Conference Call On November 4, 2015 At 4:30 P.M. Eastern Time 10/22/2015 11:22:09 AM
Massachusetts Debuts Three Biotech IPOs for $235M As Market Roars 6/22/2015 7:06:04 AM
Lantheus Medical Imaging's First Phase 3 Study Of Novel PET Cardiac Imaging Agent Flurpiridaz F 18 Data Show Statistically And Clinically Significant Improvements 5/4/2015 6:53:36 AM
Lantheus Medical Imaging Revives IPO 11/12/2014 6:39:12 AM
Lantheus Medical Imaging Eyes IPO Worth Up To $125 Million 6/26/2014 7:02:19 AM
Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time 11/7/2013 7:58:26 AM
Lantheus Medical Imaging Releases Preliminary Results from Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease 10/30/2013 7:25:45 AM
Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013 9/10/2013 6:45:21 AM
Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time 8/2/2013 7:02:38 AM